TWRFF yields 1692.05% · PFE yields 6.13%● Live data
📍 TWRFF pulled ahead of the other in Year 1
Combined, TWRFF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TWRFF + PFE for your $10,000?
Tower Resources Ltd. engages in the acquisition, evaluation, and exploration of mineral properties in Canada. The company primarily explores for gold, silver, and copper deposits. Its properties include the Rabbit North project that comprises 34 mineral tenures covering an area of 16,400 hectares located in the Kamloops mining division of British Columbia; the Nechako gold project, which include 10 mineral tenures totaling 2,975 hectares in the Nechako Plateau Region of central British Columbia; the Belle copper-gold porphyry project consisting of seven claims totaling 1691 hectares located in the Toodoggone district; and the More Creek project comprising 5 mineral tenures totaling 6,430 hectares situated in the Golden Triangle District of northwest British Columbia. The company was formerly known as Tower Energy Ltd. and changed its name to Tower Resources Ltd. in September 2011. Tower Resources Ltd. was incorporated in 1988 and is headquartered in Squamish, Canada.
Full TWRFF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.